Jun 15, 2020
MBio Delivers Rapid Cytokine Test System for COVID-19 Research
May 29, 2020
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020
May 05, 2020
Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune(TM)
Apr 01, 2020
Salimetrics' Growing List of Cytokines Which Can Be Reliably Tested in Saliva Now Includes IL-17A, IL-5, and IL-7 for Fast, Easy Salivary Biomarker Analysis
Mar 25, 2020
Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study
Nov 09, 2019
Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 08, 2019
Latest Developments in the Interleukin-2 (IL-2) Research and Development, 2019 Report
Oct 02, 2019
Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 30, 2019
Medicenna Presented Promising Preclinical Results from its IL-2 Superkine Platform at the 5th Annual International Cancer Immunotherapy Conference
Sep 11, 2019
AllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors
Jul 31, 2019
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
Jul 26, 2019
Th17 Inflammatory Pathway Therapeutics Markets, 2022
Jun 20, 2019
Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
May 22, 2019
Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress
May 06, 2019
Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Ra Antibody CBP-201
Apr 02, 2019
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Mar 01, 2019
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
Nov 09, 2018
Synthorx to Present Preclinical Data for THOR-707, a "Not-Alpha" IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018
Sep 27, 2018
Medicenna Solidifies Patent Protection For Long-Acting IL-2 Superkines
Aug 22, 2018
Nuevolution Discloses the Identity of its "Cytokine X" Program being Interleukin IL-17A and Initiates Promotion of its Small Molecule IL-17A Inhibitor Program Targeting Inflammatory Diseases